Literature DB >> 1386261

Correlation between interferon (IFN) alpha resistance and deletion of the IFN alpha/beta genes in acute leukemia cell lines suggests selection against the IFN system.

O R Colamonici1, P Domanski, L C Platanias, M O Diaz.   

Abstract

Homozygous and hemizygous deletions of the interferon A (IFNA) and IFNB genes have been frequently observed in acute leukemia cell lines, primary acute leukemia cases, and gliomas. Because IFNs have an antiproliferative effect, selection against the IFN alpha/beta system could play a role or accompany the development of the malignant phenotype. Although the deletion of the IFNA/B genes could interrupt an autocrine loop that controls cell proliferation, cells would still respond to exogenous IFN alpha/beta and, thus, lesions at the receptor or signal transduction level should also be present to render cells resistant to exogenous IFN alpha/beta. To test if selection against the IFN system was operating in acute leukemias, the sensitivity to the antiproliferative effect of IFN alpha 2 was studied in acute leukemia cell lines with and without alterations of the IFNA/B genes. We found that 10 of 11 acute leukemia cell lines with alterations of the IFNA/B genes were resistant to the antiproliferative effect of IFN alpha 2, whereas only two of eight cell lines with normal IFNA/B genes were IFN-resistant. We then examined the possibility that an alteration of the receptor expression could account for the lack of response to IFN alpha 2. No significant alteration in the expression or structure of the IFN alpha receptor was observed. We also studied the downmodulation of the alpha subunit of the IFN alpha receptor upon IFN alpha 2 binding. One cell line with deletion of the IFNA/B genes showed impaired downmodulation of the IFN alpha receptor. The data presented here suggest that selection against the IFN alpha/beta system could play a role or accompany the development of the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386261

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Constitutive type I interferon modulates homeostatic balance through tonic signaling.

Authors:  Daniel J Gough; Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone; David E Levy
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

2.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 3.  Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

Authors:  Diana Saleiro; Leonidas C Platanias
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

4.  AMPK as a therapeutic target in renal cell carcinoma.

Authors:  Jennifer Woodard; Sonali Joshi; Benoit Viollet; Nissim Hay; Leonidas C Platanias
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

5.  Genomic analysis and mRNA expression of equine type I interferon genes.

Authors:  Olivier Detournay; David A Morrison; Bettina Wagner; Behdad Zarnegar; Eva Wattrang
Journal:  J Interferon Cytokine Res       Date:  2013-06-17       Impact factor: 2.607

6.  Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins.

Authors:  E Petricoin; M David; H Fang; P Grimley; A C Larner; S Vande Pol
Journal:  Mol Cell Biol       Date:  1994-02       Impact factor: 4.272

7.  The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Authors:  Diana M Rommelfanger; Marta Compte; Marta C Grau; Rosa M Diaz; Elizabeth Ilett; Luis Alvarez-Vallina; Jill M Thompson; Timothy J Kottke; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2012-09-25       Impact factor: 11.454

8.  Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status.

Authors:  Song Yao; Chi-Chen Hong; Susan E McCann; Gary Zirpoli; Lei Quan; Zhihong Gong; Candace S Johnson; Donald L Trump; Christine B Ambrosone
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

9.  Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.

Authors:  Sheng Wei Loh; Wei Lun Ng; Kok Siong Yeo; Yat-Yuen Lim; Chee-Kwee Ea
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

10.  HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells.

Authors:  Sami Kukkonen; Maria Del Pilar Martinez-Viedma; Nayoung Kim; Mariana Manrique; Anna Aldovini
Journal:  Retrovirology       Date:  2014-04-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.